TMDX:NSD-TransMedics Group Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 127.28

Change

-5.37 (-4.05)%

Market Cap

USD 3.02B

Volume

0.92M

Analyst Target

USD 21.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-07 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-9.24 (-7.24%)

USD 50.65B
ALGN Align Technology Inc

+3.74 (+1.48%)

USD 19.10B
PODD Insulet Corporation

+3.70 (+2.15%)

USD 12.61B
SWAV Shockwave Medical Inc

-0.08 (-0.02%)

USD 12.55B
BRKR Bruker Corporation

-7.01 (-9.66%)

USD 11.23B
MASI Masimo Corporation

-0.76 (-0.60%)

USD 6.74B
PRCT Procept Biorobotics Corp

+0.12 (+0.19%)

USD 3.44B
AXNX Axonics Modulation Technologie..

+0.12 (+0.18%)

USD 3.42B
TNDM Tandem Diabetes Care Inc

+1.68 (+3.25%)

USD 3.34B
LIVN LivaNova PLC

+0.36 (+0.60%)

USD 3.23B

ETFs Containing TMDX

CYBG:LSE VanEck Bionic Engineering.. 3.88 % 0.00 %

-0.01 (-0.06%)

USD 6.37M
XHE SPDR® S&P Health Care Eq.. 2.65 % 0.35 %

+0.17 (+-0.06%)

USD 0.26B
MMSC First Trust Multi-Manager.. 1.36 % 0.00 %

-0.03 (-0.06%)

USD 0.02B
FFTY Innovator IBD® 50 ETF 0.00 % 0.80 %

-0.27 (-0.06%)

USD 0.09B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 61.26% 92% A 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 61.26% 92% A 92% A
Trailing 12 Months  
Capital Gain 68.67% 93% A 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 68.67% 93% A 90% A-
Trailing 5 Years  
Capital Gain 405.28% 97% N/A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 405.28% 97% N/A 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 61.04% 91% A- 92% A
Dividend Return 61.04% 91% A- 92% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 94.80% 32% F 16% F
Risk Adjusted Return 64.39% 96% N/A 88% B+
Market Capitalization 3.02B 93% A 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.